- Home
- SER vs WHWK Comparison
SER vs WHWK Comparison
Compare SER & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- WHWK
- Stock Information
- Founded
- SER 2017
- WHWK 2007
- Country
- SER United States
- WHWK United States
- Employees
- SER N/A
- WHWK N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- WHWK Health Care
- Exchange
- SER Nasdaq
- WHWK Nasdaq
- Market Cap
- SER 53.5M
- WHWK 48.3M
- IPO Year
- SER 2018
- WHWK N/A
- Fundamental
- Price
- SER $5.80
- WHWK $1.58
- Analyst Decision
- SER Strong Buy
- WHWK
- Analyst Count
- SER 1
- WHWK 0
- Target Price
- SER $11.00
- WHWK N/A
- AVG Volume (30 Days)
- SER 12.2K
- WHWK 181.8K
- Earning Date
- SER 05-24-2025
- WHWK 05-19-2025
- Dividend Yield
- SER N/A
- WHWK N/A
- EPS Growth
- SER N/A
- WHWK N/A
- EPS
- SER N/A
- WHWK N/A
- Revenue
- SER $56,000.00
- WHWK $25,983,000.00
- Revenue This Year
- SER N/A
- WHWK $30.85
- Revenue Next Year
- SER N/A
- WHWK N/A
- P/E Ratio
- SER N/A
- WHWK N/A
- Revenue Growth
- SER N/A
- WHWK 6.69
- 52 Week Low
- SER $3.81
- WHWK $1.21
- 52 Week High
- SER $14.57
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- SER 55.22
- WHWK N/A
- Support Level
- SER $5.12
- WHWK N/A
- Resistance Level
- SER $6.61
- WHWK N/A
- Average True Range (ATR)
- SER 0.49
- WHWK 0.00
- MACD
- SER -0.01
- WHWK 0.00
- Stochastic Oscillator
- SER 56.45
- WHWK 0.00
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.